I strongly doubt this. More significant trialling will have to be done to demonstrate that what the higher sensitivity may pick up is indeed tumorous. And with new scanners and we’re yet to see how they also serve to improve images for CU6 diagnostic products. I suspect there’ll be marked improvements with both products and the preference to shift to CU6’s range.
And they will not be ubiquitous in the market. They will only go into new/expanding clinics and the lucky major hospitals initially. After that it will take many years for older systems to be replaced as commercial scanning groups will still be able to make a buck out of them.
The wheels of new technology roll out move very, very slowly, especially when they come with such a large price tag
CU6 Price at posting:
$6.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)